Diagnosis and Management of IgM Kappa Monoclonal Gammopathies

Introduction to IgM Kappa Monoclonal Gammopathies

The presence of an IgM kappa monoclonal spike on serum electrophoresis indicates a clonal B-cell or plasma cell disorder, requiring differentiation between IgM MGUS, Waldenström macroglobulinemia (WM), or IgM multiple myeloma, based on bone marrow findings and presence of end-organ damage, as recommended by the National Comprehensive Cancer Network 1, 2
IgM MGUS is defined by serum IgM M-protein <30 g/L, bone marrow lymphoplasmacytic infiltration <10%, and absence of end-organ damage, with a 1% annual risk of progression to lymphoproliferative disorder, according to the International Myeloma Society 3, 4, 5

Waldenström Macroglobulinemia requires both monoclonal IgM protein and bone marrow infiltration by lymphoplasmacytic cells consistent with lymphoplasmacytic lymphoma (LPL), with a characteristic immunophenotype, as stated by the European Society for Medical Oncology 6, 1, 2
IgM Multiple Myeloma is a rare entity with plasma cell predominance, distinguished by bone marrow showing ≥10% clonal plasma cells and presence of CRAB criteria, according to the American Society of Clinical Oncology 1, 3, 4

Immediate laboratory evaluation must include serum protein electrophoresis with quantification, serum immunofixation electrophoresis, quantitative immunoglobulins, complete blood count, comprehensive metabolic panel, and serum free light chain assay, as recommended by the National Comprehensive Cancer Network 1, 2, 6
Bone marrow examination is mandatory for any patient with IgM M-protein ≥30 g/L, presence of unexplained anemia, renal insufficiency, hypercalcemia, or bone lesions, and should include aspirate, biopsy, flow cytometry/immunohistochemistry, and MYD88 (L265P) mutation testing, according to the International Myeloma Society 1, 2, 5

The concentration of the M-spike guides urgency and extent of evaluation, with IgM <15 g/L considered low-risk, IgM 15-30 g/L intermediate-risk, and IgM ≥30 g/L meeting the threshold for smoldering or symptomatic WM, as stated by the European Society for Medical Oncology 5, 3, 4
Treatment is indicated only for symptomatic disease, with symptoms requiring treatment in WM including hemoglobin <10 g/dL, platelet count <100 × 10⁹/L, symptomatic hyperviscosity, and symptomatic organomegaly or lymphadenopathy, according to the American Society of Clinical Oncology 6, 1, 2
Asymptomatic patients should be monitored every 3-6 months with serum protein electrophoresis, CBC, and comprehensive metabolic panel, with treatment initiated only when symptoms develop, as recommended by the National Comprehensive Cancer Network 6